This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Yates, A. J. Articles by Rice, J. M. Search for Related Content PubMed PubMed Citation Articles by Yates, A. J. Articles by Rice, J. M.

Effects of Interferon and Gangliosides on Growth of Cultured Human Glioma and Fetal Brain Cells¹

Departments of Pathology (Neuropathology) [A. J. Y., R. E. S., P. J. E., D. L. M.], The Ohio State University, Columbus, Ohio 43210, and The Batelle Memorial Institute, Columbus, Ohio [J. M. R.]

Human ß-interferon (IFN) induced an antiviral state in two fetal brain and six glioma cell lines. The growth-inhibitory effect of IFN was most pronounced on three glioblastoma lines and least on fetal brain and oligodendroglioma cells; IFN growth inhibition of one schwannoma and one anaplastic cell line was intermediate between the two other groups. Thus, the growth-inhibitory effect of IFN generally correlated with the degree of anaplasia of the tissue from which the cells were derived. IFN (1000 units/ml) had to be present for 24 to 48 hr to have a significant inhibitory effect on growth of glioblastoma (12–18) cells. However, growth inhibition of 12–18 cells exposed to IFN for 3 days persisted for 3 weeks. Both sialic acid-N-acetylgalactosamine ganglioside and a mixture of normal human brain gangliosides (50 µM) inhibited growth of fetal brain (CHII) but not glioblastoma 12–18 cells. However, preincubation of cells with either sialic acid-N-acetylgalactosamine or a mixture of gangliosides did not augment the growth-inhibitory effects of IFN on either CHII or 12–18. These results indicate that gangliosides and IFN may be operating through different mechanisms to cause growth inhibition.

¹ This investigation was supported by USPHS Grant CA-31564 awarded by the National Cancer Institute, Department of Health and Human Services, and by the Department of Pathology and College of Medicine, Ohio State University.

² To whom requests for reprints should be addressed, at Division of Neuropathology, Room 111, 473 West 12th Avenue, Columbus, OH 43210.

Received 3/ 5/84. Accepted 11/30/84.